

Information Form and Checklist

(ASX Listing)

Name of entity

ABN/ACN/ARBN/ARSN

Clarity Pharmaceuticals Ltd (Clarity)

36 143 005 341

We (the entity named above) supply the following information and documents to support our application for admission to the official list of ASX Limited (ASX) as an ASX Listing.

Note: by giving an Appendix 1A *Application for Admission to the ASX Official List (ASX Listing)* to ASX, the entity is taken to have warranted that all of the information and documents it has given, or will give, to ASX in connection with its admission to the official list and the quotation of its securities are, or will be, accurate, complete and not misleading. It also indemnifies ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from, or connected with, any breach of that warranty (see Appendix 1A of the ASX Listing Rules).

The information and documents referred to in this Information Form and Checklist (including any annexures to it) are covered by the warranty and indemnity mentioned above.

Terms used in this Information Form and Checklist and in any Annexures have the same meaning as in the ASX Listing Rules.

Part 1 – Key Information

Instructions: please complete each applicable item below. If an item is not applicable, please mark it as "N/A".

All entities – corporate details¹

Type of Australian registration number given above (eg ABN, ACN, ARSN or ARBN)	ABN 36 143 005 341 ACN 143 005 341
Legal entity identifier, if applicable	N/A
Place of incorporation or establishment	New South Wales, Australia
Date of incorporation or establishment	8 April 2010 (and converted to a public company on 3 February 2017)
Legislation under which incorporated or established	<i>Corporations Act 2001 (Cth)</i>
Address of registered office in place of incorporation or establishment	'National Innovation Centre' Suite 212a 2-4 Cornwallis Street Eveleigh, 2015, NSW

¹ If the entity applying for admission to the official list is a stapled group, please provide these details for each entity comprising the stapled group.

Main business activity	<p>Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.</p> <p>Theranostic radiopharmaceuticals have four main elements: a radioisotope, cage, linker and targeting ligand. The biological targeting agent (targeting ligand) is designed to find and bind/stick to specific proteins on cancer cells. Once the targeting ligand has found the tumour, the radioisotope, connected to the targeting ligand via the linker and held inside a cage (chelator), can act in that location, either emitting radiation to be picked up by an imaging device (diagnostic radioisotope) or by destroying the cancer cells (therapeutic radioisotope).</p> <p>Clarity's SAR Technology is ideally suited for use with copper isotopes enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in the oncology industry.</p> <p>The Company utilises the Copper Pair Theranostics (CPT) to form the basis for the development of next-generation radiopharmaceutical products. Clarity leverages CPT and its proprietary SAR Technology Platform in the development of the "perfect pairing" of copper-64 (⁶⁴Cu) and copper-67 (⁶⁷Cu) for diagnosis and therapy of cancer respectively.</p> <p>Clarity's products are at the clinical development stage and have not yet generated income. Accordingly, the Company has been reliant on grants, the Australian R&D Tax Incentive and investors to fund its product research, development and clinical trials to date.</p> <p>Further Details are set out in Section 1 and Section 3 of the Prospectus.</p>
Country where main business activity is mostly carried on	Australia and the United States of America (with some historical operations in Belgium that will be wound up in due course).
Other exchanges on which the entity is listed	None
Street address of principal administrative office	'National Innovation Centre' Suite 212a 2-4 Cornwallis Street Eveleigh NSW 2015
Postal address of principal administrative office	Same as above
Telephone number of principal administrative office	+61 2 9209 4037
E-mail address for investor enquiries	investor@claritypharmaceuticals.com
Website URL	https://www.claritypharmaceuticals.com/

All entities – board and senior management details²

Full name and title of chairperson of directors	Dr Alan John Taylor
---	---------------------

² If the entity applying for admission to the official list is a trust, enter the board and senior management details for the responsible entity of the trust.

Full names of all existing directors	Ms Rosanne Elizabeth Robinson Dr Christopher Graham Roberts Dr Alan John Taylor Dr Thomas Ramdahl Dr Charles Gillies O'Bryan-Tear
Full names of any persons proposed to be appointed as additional or replacement directors	Mr Robert Bain Thomas (appointment is effective upon listing on the ASX)
Full name and title of CEO/managing director	Dr Colin David Biggin
Email address of CEO/managing director	cbiggin@claritypharmaceuticals.com
Full name and title of CFO	Mr Robert Cochrane Vickery
Email address of CFO	robert.vickery@claritypharmaceuticals.com
Full name and title of company secretary	Mr Robert Cochrane Vickery
Email address of company secretary	robert.vickery@claritypharmaceuticals.com

All entities – ASX compliance contact details³

Full name and title of ASX contact(s)	Robert Vickery (Joint Company Secretary) Sarah Prince (Joint Company Secretary)
Business address of ASX contact(s)	Robert Vickery (Company Secretary) Suite 212, 4 Cornwallis St EVELIEGH NSW 2015 T: 02 9209 4037 M: 0414 932 063 robert.vickery@claritypharmaceuticals.com With effect upon listing: Sarah Prince Company Matters Level 12, 680 George Street, Sydney NSW 2000 T: +61 2 8280 7355 M: +61 439 414 408 prince@company matters.com.au

³ Under Listing Rule 1.1 Condition 13, a listed entity must appoint a person responsible for communication with ASX on Listing Rule matters. You can appoint more than one person to cater for situations where the primary nominated contact is not available.

Business phone number of ASX contact(s)	As above
Mobile phone number of ASX contact(s)	As above
Email address of ASX contact(s)	As above

All entities – investor relations contact details

Full name and title of person responsible for investor relations	Alan Taylor (Executive Chair)
Business phone number of person responsible for investor relations	T: 02 9209 4037 M: +61 (0)413 871 165
Email address of person responsible for investor relations	ataylor@claritypharmaceuticals.com

All entities – auditor details⁴

Full name of auditor	Grant Thornton Audit Pty Ltd
----------------------	------------------------------

All entities – registry details⁵

Name of securities registry	Link Market Services Limited (ACN 083 214 537)
Address of securities registry	Level 12, 680 George Street, Sydney NSW 2000
Phone number of securities registry	+61 1300 554 474
Fax number of securities registry	+61 2 9287 0303
Email address of securities registry	registrars@linkmarketservices.com.au
Type of subregisters the entity will operate ⁶	ASX's Clearing House Electronic Subregister System (CHESS) and issuer sponsored subregister

All entities – key dates

Annual balance date	30 June
Month in which annual meeting is usually held (or intended to be held) ⁷	October

⁴ In certain cases, ASX may require the applicant to provide information about the qualifications and experience of its auditor for release to the market before quotation commences (see Guidance Note 1 section 2.12).

⁵ If the entity has different registries for different classes of securities, please indicate clearly which registry details apply to which class of securities.

⁶ Example: CHESS and issuer sponsored subregisters (see Guidance Note 1 section 3.23).

⁷ May not apply to some trusts.

Months in which dividends or distributions are usually paid (or are intended to be paid)	Clarity has never paid a dividend and the directors have no current intention of declaring or paying any dividends in the foreseeable future. It is the directors' intention to utilise the offer proceeds received by Clarity in order to maximise the company's growth potential. The ability of Clarity to declare and pay a dividend depends on its success in developing and commercialising one or more products and there can be no certainty that this will occur. Accordingly, there can be no certainty that Clarity will ever declare and pay a dividend.
--	---

Trusts — additional details

Name of responsible entity	N/A
Full names of the members of the compliance committee (if any)	N/A

Entities incorporated or established outside Australia — additional details

Name and address of the entity's Australian agent for service of process	N/A
Address of registered office in Australia (if any)	N/A

Entities listed or to be listed on another exchange or exchanges

Name of the other exchange(s) where the entity is or proposes to be listed	N/A
Is the ASX listing intended to be the entity's primary or secondary listing	N/A

Part 2 – Checklist Confirming Compliance with Admission Requirements

Instructions: please indicate in the "Location/Confirmation" column for each item below and in any Annexures where the information or document referred to in that item is to be found (eg in the case of information, the specific page reference in the Offer Document where that information is located or, in the case of a document, the folder tab number where that document is located). If the item asks for confirmation of a matter, you may simply enter "Confirmed" in the "Location/Confirmation" column. If an item is not applicable, please mark it as "N/A".

In this regard, it will greatly assist ASX and speed up its review of the application if the various documents referred to in this Checklist and any Annexures (other than the 2 copies of the applicant's Offer Document (as lodged with ASIC) referred to in item 4 and the 10 printed versions of the final Offer Document referred to in note 10) are provided in a folder separated by numbered tabs and if the entity's constitution and copies of all material contracts are provided both in hard copy and in electronic format.

Note that completion of this Checklist and any Annexures is not to be taken to represent that the entity is necessarily in full or substantial compliance with the ASX Listing Rules or that ASX will admit the entity to its official list. Admission to the official list is in ASX's absolute discretion and ASX may refuse admission without giving any reasons (see Listing Rule 1.19).

A reference in this Checklist and in any Annexures to the "Offer Document" means the listing prospectus, product disclosure statement or information memorandum lodged by the applicant with ASX pursuant to Listing Rule 1.1 Condition 3.

If the applicant lodges a supplementary or replacement prospectus, product disclosure statement or information memorandum with ASX, ASX may require it to update this Checklist and any Annexures by reference to that document.

All entities – key supporting documents

Nº Item	Location/Confirmation
1. A copy of the entity's certificate of incorporation, certificate of registration or other evidence of status (including any change of name)	See Doc 1 – Certificate of Registration 13 Feb 2017 - Conversion to Public Company.
2. A copy of the entity's constitution (Listing Rule 1.1 Condition 2) ⁸	See Doc 2 - Constitution of Clarity Pharmaceuticals Ltd (effective upon listing) – approved by members of the Company at a General Meeting on 13 July 2021 which is to become effective on Listing.
3. Either: (a) confirmation that the entity's constitution includes the provisions of Appendix 15A or Appendix 15B (as applicable); or (b) a completed checklist that the constitution complies with the Listing Rules (Listing Rule 1.1 Condition 2) ⁹	The provisions of Appendix 15A are included in Clarity's constitution that will be effective from Listing.
4. An electronic version and 2 hard copies of the Offer Document, as lodged with ASIC (Listing Rule 1.1 Condition 3) ¹⁰	See Doc 3 – Clarity Pharmaceuticals Ltd Prospectus (as lodged with ASIC) (Prospectus). Hard copies to follow as directed pending COVID-19 restrictions.
5. Where in the Offer Document is the prominent statement that ASX takes no responsibility for the contents of the Offer Document (Listing Rule 1.1 Condition 3)?	See Pages 1, 33, 156, and 166 of the Prospectus.
6. Original executed ASX Online agreement confirming that documents may be given to ASX and authenticated electronically (Listing Rule 1.1 Condition 14) ¹¹	See Doc 4 – ASX online agreement (executed).
7. If the entity's corporate governance statement ¹² is included in its Offer Document, the page reference where it is included. Otherwise, a copy of the entity's corporate governance statement (Listing Rule 1.1 Condition 16)	See Doc 5 – Clarity Pharmaceuticals Ltd - Corporate Governance Statement.
8. If the entity will be included in the S & P All Ordinaries Index on admission to the official list, ¹³ where in its Offer Document does it state that it will have an audit committee (Listing Rule 1.1 Condition 17)?	Clarity will have an Audit and Risk Committee in place with effect from listing. See Prospectus section 6.6.1.4(a).

⁸ It will assist ASX if the copy of the constitution is provided both in hard copy and in electronic format.

⁹ An electronic copy of the checklist is available from the ASX Compliance Downloads page on ASX's website.

¹⁰ The applicant should also provide 10 printed copies of the final Offer Document to ASX as soon as they are available.

¹¹ An electronic copy of the *ASX Online Agreement* is available from the ASX Compliance Downloads page on ASX's website.

¹² The entity's "corporate governance statement" is the statement disclosing the extent to which the entity will follow, as at the date of its admission to the official list, the recommendations set by the ASX Corporate Governance Council. If the entity does not intend to follow all the recommendations on its admission to the official list, the entity must separately identify each recommendation that will not be followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it intends to adopt in lieu of the recommendation.

¹³ If the entity is unsure whether they will be included in the S & P All Ordinaries Index on admission to the official list, they should contact ASX or S & P.

N° Item	Location/Confirmation
9. If the entity will be included in the S & P / ASX 300 Index on admission to the official list, ¹⁴ where in its Offer Document does it state that it will comply with the recommendations set by the ASX Corporate Governance Council in relation to the composition and operation of the audit committee (Listing Rule 1.1 Condition 17)?	<p>The Company will comply with the ASX Recommendations in relation to the composition and operation of the committee, which will be comprised of at least three Non-Executive Directors, a majority of whom are independent, and an independent chair.</p> <p>See Section 6.6.1.4(a) of the Prospectus.</p>
10. If the entity will be included in the S & P / ASX 300 Index on admission to the official list, ¹⁵ where in its Offer Document does it state that it will have a remuneration committee comprised solely of non-executive directors (Listing Rule 1.1 Condition 18)	<p>Clarity is not expected to form part of the S & P / ASX 300 Index on admission.</p> <p>In any event, the Company will have a Nomination and Remuneration Committee in place from admission (which will only partially comply with the ASX Recommendations in relation to the composition and operation).</p> <p>See Section 6.6.1.4(b) of the Prospectus.</p>
11. If the entity's trading policy is included in its Offer Document, the page reference where it is included. Otherwise, a copy of the entity's trading policy (Listing Rule 1.1 Condition 19)	<p>See Section 6.6.1.5(c) of the Prospectus for a summary of the entity's trading policy.</p> <p>See Doc 6 – Clarity Pharmaceuticals Ltd Trading Policy.</p>
12. For each director or proposed director, the CEO or proposed CEO, and the CFO or proposed CFO (together, "relevant officers") of the entity at the date of listing, ¹⁶ a list of the countries in which they have resided over the past 10 years (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21) ¹⁷	<p>Colin David Biggin – Australia, Norway Robert Vickery - Australia Rosanne Elizabeth Robinson - Australia Christopher Graham Roberts - Australia Alan John Taylor – Australia Thomas Ramdahl – Norway Charles Gillies O'Bryan-Tear – UK Robert Bain Thomas – Australia</p>
13. For each relevant officer, a list of any other names or alias they have used in the past 10 years, including any maiden name or married name ¹⁸ (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)	<p>Rosanne Elizabeth Robinson's former names are the following:</p> <ul style="list-style-type: none"> - Rosanne Elizabeth Paine; and - Rosanne Elizabeth Pain.

¹⁴ If the entity is unsure whether they will be included in the S & P / ASX 300 Index on admission to the official list, they should contact ASX or S & P.

¹⁵ If the entity is unsure whether they will be included in the S & P / ASX 300 Index on admission to the official list, they should contact ASX or S & P.

¹⁶ If the entity applying for admission to the official list is a trust, references in items 12, 13, 14, 15, 16, 17 and 18 to a relevant officer mean a relevant officer of the responsible entity of the trust.

¹⁷ The information referred to in items 12, 13, 14, 15, 16, 17 and 18 is required so that ASX can be satisfied that the relevant officer is of good fame and character under Listing Rule 1 Condition 20.

¹⁸ The sample statutory declaration referred to in item 18 below addresses this requirement. Note that if the relevant officer has used another name or alias (including a maiden name or married name) in the past 10 years, the criminal record and bankruptcy checks referred to in items 14, 15, 16, 17 must cover all of the names or aliases the relevant officer has used over that period.

Nº Item	Location/Confirmation
<p>14. For each relevant officer who is or has in the past 10 years been a resident of Australia, an original or certified true copy of a national criminal history check obtained from the Australian Federal Police, a State or Territory police service or a broker accredited by Australian Criminal Intelligence Commission which is not more than 12 months old (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)</p>	<p>See Folder 1 – Relevant officer national criminal history checks – Docs 1.1 – 1.6</p>
<p>15. For each relevant officer who is or has in the past 10 years been a resident of a country other than Australia, an original or certified true copy of an equivalent national criminal history check to that mentioned in item 14 above for each country in which the relevant officer has resided over the past 10 years (in English or together with a certified English translation) which is not more than 12 months old or, if such a check is not available in any such country, a statutory declaration¹⁹ from the relevant officer confirming that fact and that he or she has not been convicted in that country of:</p> <p>(a) any criminal offence involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of his or her duties as a director or officer of a company or other entity; or</p> <p>(b) any other criminal offence which at the time carried a maximum term of imprisonment of five years or more (regardless of the period, if any, for which he or she was sentenced),</p> <p>or, if that is not the case, a statement to that effect and a detailed explanation of the circumstances involved (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)</p>	<p>See Folder 1 – Relevant officer national criminal history checks – Docs 1.7 – 1.10</p>
<p>16. For each relevant officer who is or has in the past 10 years been a resident of Australia, an original or certified true copy of a search of the Australian Financial Security Authority National Personal Insolvency Index which is not more than 12 months old (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)</p>	<p>See Folder 2 – Relevant officer insolvency checks – Docs 2.1 – 2.6</p>
<p>17. For each relevant officer who is or has in the past 10 years been a resident of a country other than Australia, an original or certified true copy of an equivalent national bankruptcy check to that mentioned in item 16 above for each country in which the relevant officer has resided over the past 10 years (in English or together with a certified English translation) which is not more than 12 months old or if such a check is not available in any such country, a statutory declaration²⁰ from the relevant officer confirming that fact and that he or she has not been declared a bankrupt or been an insolvent under administration in that country or, if that is not the case, a statement to that effect and a detailed explanation of the circumstances involved (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)</p>	<p>See Folder 2 - Relevant officer insolvency checks – Docs 2.7 – 2.9</p>
<p>18. A statutory declaration²¹ from each relevant officer specifying whether they have used any other name or alias in the past 10 years and confirming that:</p> <p>(a) the relevant officer has not been the subject of any criminal or civil penalty proceedings or other enforcement action by any government agency in which he or she was found to have engaged in behaviour involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of duty;</p> <p>(b) the relevant officer has not been refused membership of, or had their membership suspended or cancelled by, any professional body on the ground that he or she has engaged in behaviour involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of duty;</p> <p>(c) the relevant officer has not been the subject of any disciplinary action (including any censure, monetary penalty or banning order) by a securities</p>	<p>See Folder 3 - Relevant officer statutory declarations.</p>

¹⁹ The sample statutory declaration referred to in item 18 below also addresses this requirement.

²⁰ The sample statutory declaration referred to in item 18 below also addresses this requirement.

²¹ A sample statutory declaration is available from the ASX Compliance Downloads page on ASX's website.

N° Item	Location/Confirmation
<p>exchange or other authority responsible for regulating securities markets for failure to comply with his or her obligations as a director or officer of a listed entity;</p> <p>(d) no listed entity of which he or she was a relevant officer (or, in the case of a listed trust, in respect of which he or she was a relevant officer of the responsible entity of the trust) at the time of the relevant conduct has been the subject of any disciplinary action (including any censure, monetary penalty, suspension of trading or termination of listing) by a securities exchange or other authority responsible for regulating securities markets for failure to comply with its obligations under the Listing Rules applicable to that entity; and</p> <p>(e) the relevant officer is not aware of any pending or threatened investigation or enquiry by a government agency, professional body, securities exchange or other authority responsible for regulating securities markets that could lead to proceedings or action of the type described in (a), (b), (c) or (d) above,</p> <p>or, if the relevant officer is not able to give such confirmation, a statement to that effect and a detailed explanation of the circumstances involved (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)</p>	

19. A specimen certificate/holding statement for each class of securities to be quoted or a specimen holding statement for CDIs (as applicable)	See Doc 13 – Clarity Broker Offer Application Form and Doc 14 – Clarity Initial Public Offer Holding Statement.
---	---

<p>20. Please either:</p> <p>(a) enter “Confirmed” in the column to the right to confirm that the entity has not previously applied for, and been refused or withdrawn its application for, admission to the official list of another securities exchange, or</p> <p>(b) attach a statement explaining the circumstances and state the location of that statement</p>	Confirmed
---	-----------

21. Please enter “Confirmed” in the column to the right to confirm that the entity has paid its initial listing fee ²²	Confirmed
---	-----------

All entities – group structure

22. Where in the Offer Document is there a diagram showing the group structure of the entity, identifying (where applicable) each material child entity and the nature and location of the business activities it undertakes	See Section 10.3 (Corporate structure) (page 202) of the Prospectus.
--	--

23. If the entity has any material child entities, where in the Offer Document is there a list of all such child entities stating, in each case, its name, where it is incorporated or established, the nature of its business and the entity’s percentage holding in it?	See Section 10.3 (Corporate structure) (page 202) of the Prospectus.
---	--

24. If the entity has any material investments in associated entities for which it will apply equity accounting, where in the Offer Document is there a list of all such associated entities stating, in each case, its name, where it is	N/A
---	-----

²² See Guidance Notes 15 and 15A for the fees payable on the application. You can also use the ASX online equity listing fees calculator: <http://www.asx.com.au/prices/cost-listing.htm>. Payment should be made either by cheque made payable to ASX Operations Pty Ltd or by electronic funds transfer to the following account:

Bank: National Australia Bank
Account Name: ASX Operations Pty Ltd
BSB: 082 057
A/C: 494728375
Swift Code (Overseas Customers): NATAAU3202S

If payment is made by electronic funds transfer, please email your remittance advice to ar@asx.com.au or fax it to (612) 9227-0553, describing the payment as the “initial listing fee” and including the name of the entity applying for admission, the ASX home branch where the entity has lodged its application (ie Sydney, Melbourne or Perth) and the amount paid.

N° Item	Location/Confirmation
incorporated or established, the nature of its business and the entity's percentage holding in it?	
25. If the entity has a material interest in a joint venture, where in the Offer Document is there a description of the joint venture agreement, including the parties to the agreement and their respective rights and obligations under the agreement?	N/A
26. If the entity does not hold its material assets and business operations directly itself or indirectly through a child entity, where in the Offer Document is there an explanation of why that structure has been employed and the risks associated with it?	<p>N/A</p> <p>All key assets are owned by the Company as set out in the following Sections of the Prospectus:</p> <ul style="list-style-type: none"> - 9 (Intellectual Property Report) (pages 176 - 200); and - 3 (Company Overview) (pages 74 - 104).

All entities – capital structure

<p>27. Where in the Offer Document is there a table showing the existing and proposed capital structure of the entity, broken down as follows:</p> <p>(a) the number and class of each equity security and each debt security currently on issue; and</p> <p>(b) the number and class of each equity security and each debt security proposed to be issued between the date of this application and the date the entity is admitted to the official list; and</p> <p>(c) the resulting total number of each class of equity security and debt security proposed to be on issue at the date the entity is admitted to the official list; and</p> <p>(d) the number and class of each equity security proposed to be issued following admission in accordance with material contracts or agreements?</p> <p>Note: This applies whether the securities are to be quoted on ASX or not. If the entity is proposing to issue a minimum, maximum or oversubscription number of securities, the table should be presented to disclose each scenario.</p>	<p>See the following Sections of the Prospectus:</p> <ul style="list-style-type: none"> - Key Offer Information (page 6); - 7.1.4 (Shareholding Structure of Clarity) (pages 154 - 155); - 10.5 (Current capital structure) (page 205); and - 10.6 Capital structure following the Offer (page 205), <p>which provide Clarity's current capital structure and capital structure on listing.</p>
<p>28. If any class of securities referred to in the table mentioned in item 27 are not ordinary securities, where in the Offer Document does it disclose the terms applicable to those securities?</p> <p>Note: This applies whether the securities are to be quoted on ASX or not.</p> <p>For equity securities (other than options to acquire unissued securities or convertible debt securities), this should state whether they are fully paid or partly paid; if they are partly paid, the amount paid up and the amount owing per security; voting rights; rights to dividends or distributions; and conversion terms (if applicable).</p> <p>For options to acquire unissued securities, this should state the number outstanding, exercise prices; exercise terms and expiry dates.</p> <p>For debt securities or convertible debt securities, this should state their nominal or face value; rate of interest; dates of payment of interest; date and terms of repayment or redemption; and conversion terms (if applicable).</p>	<p>See the following Sections of the Prospectus:</p> <ul style="list-style-type: none"> - 6.4.2.6 (Directors' interests and Options) (page 139); - 7.1.4 (Shareholding Structure of Clarity) (pages 154 - 155); and - 10.7 (Options currently on issue) (pages 205 - 208). <p>No Options are proposed to be quoted on ASX and will remain unlisted.</p> <p>See Doc 10 for a copy of the China Grand Option Deed and Doc 11 for a summary note on the China Grand Options.</p> <p>All ordinary shares on issue are to be quoted.</p>
<p>29. Where in the Offer Document does it confirm that the entity's free float at the time of listing will be not less than 20% (Listing Rule 1.1 Condition 7)?</p>	<p>See Section 10.4.4 (Free Float) (page 204) of the Prospectus.</p>

N° Item	Location/Confirmation
30. Where in the Offer Document does it confirm that the issue/sale price of all securities for which the entity seeks quotation is at least 20 cents in cash (Listing Rule 2.1 Condition 2)?	See (Key Offer Details) (page 6) of the Prospectus which details the Offer Price as being \$1.40 per Share under the Offer.
31. If the entity has or proposes to have any options on issue, where in the Offer Document does it confirm that the exercise price for each underlying security is at least 20 cents in cash (Listing Rule 1.1 Condition 12)?	See the following Sections of the Prospectus: - 6.4.2.6 (Directors' interests in options) (page 139); and - 10.7 (Options) (page 205).
32. If the entity has any partly paid securities and it is not a no liability company, where in the Offer Document does it disclose the entity's call program, including the date and amount of each proposed call and whether it allows for any extension for payment of a call (Listing Rule 2.1 Condition 4)?	N/A
33. Is the entity proposing to offer any securities by way of a bookbuild? If so, please enter "Confirmed" in the column to the right to indicate that the entity is aware of the disclosure requirements for bookbuilds in Annexure A to Guidance Note 1 and has made appropriate arrangements with the bookrunner to obtain this information.	Confirmed

All entities – business information

34. Where in the Offer Document is there a description of the history of the entity?	See the following Sections of the Prospectus: - 1.1 (Overview of Clarity and its business model) (page 12); - 3.1 (Introduction to Clarity Pharmaceuticals Ltd); and - 3.2 (Clarity's proprietary SAR Technology platform) (pages 75 - 81).
35. Where in the Offer Document is there a description of the entity's existing and proposed activities and level of operations?	See the following Sections of the Prospectus: - 3.5 (Clarity's products) (pages 84 - 98); - 3.6 (Discovery program and research & development) (pages 98 - 99); and - 3.7 (Manufacturing and supply strategy) (pages 100 - 102).
36. Where in the Offer Document is there a description of the material business risks the entity faces?	See the following Sections of the Prospectus: - 1.4 (Key Risks) (pages 14 - 22); and - 5 (Key Risks) (pages 105 - 127).
37. Where in the Offer Document is there a table setting out the proposed use of the proceeds of the offer?	See the following Sections of the Prospectus: - 1.8 (Overview of the offer) (page 32); and - 7.1.3 (Sources and uses of funds) (pages 153 - 154).

All entities – related parties, promoters and advisers

38. Has the entity undertaken a placement of securities in the last 2 years in which a related party or their associates, a promoter or their associates, or an adviser involved in the offer or their associates, have participated?

If so, please attach a statement

- (a) explaining the circumstances of the placement;
- (b) listing the names and addresses of the participants in the placement, the number of securities they received in the placement and the consideration they provided for those securities; and
- (c) identifying the participants in the placement who are a related party or associate of a related party, a promoter or associate of a promoter, or an adviser or an associate of an adviser.

Yes, the Company undertook a placement across multiple tranches in 2020.

Full details of the allotments are set out in the restricted securities tables. See **Doc 8 – ASX Restricted Securities Table (Mandatory Escrow)** and **Doc 9 – Voluntary Escrow** summary (for reference). A history of all allotments is also set out in spreadsheet in **Doc 12 – Clarity Escrowed Securities and History of Allotment** (for reference in relation to escrow).

A full list of all allotments in the Company's history can be provided separately if required.

39. Does an adviser to the offer have a material interest in the success of the offer over and above normal professional fees for services rendered in connection with the offer?

If so, where in the Offer Document is there a clear and concise statement explaining in one location all of the interests that adviser has in the success of the offer, including (without limitation):

- (a) the number and type of securities in the entity in which the adviser and its associates currently have a relevant interest;
- (b) details of the consideration paid or provided by the adviser or its associates for the securities referred to in (a) above;
- (c) the fees or other consideration the adviser or an associate may receive for services provided in connection with the offer;
- (d) the fees or other consideration the adviser or an associate may receive under any ongoing mandate they may have with the entity post the offer;
- (e) if the consideration in (c) or (d) above includes any convertible securities (including options, performance shares or performance rights), details of the number and terms of those securities, the percentage of the entity's issued capital at listing they will convert into if they are converted, the value the entity believes the convertible securities are worth and the basis on which the entity has determined that value; and
- (f) if the adviser or any of its associates have participated in a placement of securities by the entity in the preceding 2 years, full details of the securities they received in the placement and the consideration they paid or provided for those securities?

See the following Sections of the Prospectus:

- 6.4.1 (Interests of advisers) (pages 136 - 137); and
- 10.11.1 (Underwriting Agreement) (page 212).

All entities – other information and documents

40. Where in the Offer Document is there a description of the entity's proposed dividend/distribution policy?

See the following Sections of the Prospectus

- 1.1 (Overview of Clarity and its business model) (page 11); and
- 4.10 (Dividend Policy) (page 113).

N° Item	Location/Confirmation
41. Does the entity have or propose to have a dividend or distribution reinvestment plan?	
If so, where are the existence and material terms of the plan disclosed in the Offer Document?	N/A
A copy of the terms of the plan	N/A
42. Does the entity have or propose to have an employee incentive scheme?	
If so, where are the existence and material terms of the scheme disclosed in the Offer Document?	See Section 6.5 (Employee incentive arrangements) (pages 143 - 146) of the Prospectus.
Where in the Offer Document is there a statement as to whether directors ²³ are entitled to participate in the scheme and, if they are, the extent to which they currently participate or are proposed to participate?	See the following Sections of the Prospectus: - 6.4.2 (Directors' interests and remuneration) (page 137); - 6.4.2.8 (Executive remuneration) (pages 141 - 143); and - 6.5 (Employee incentive arrangements) (pages 143 - 146).
A copy of the terms of the scheme	See Section 6.5.2 (Equity based remuneration) (pages 144 – 146) of the Prospectus. See also Doc 7 – Clarity's Equity Incentive Plan.
43. Has the entity entered into any material contracts (including any underwriting agreement relating to the securities to be quoted on ASX)? ²⁴	
If so, where are the existence and main terms of those material contracts disclosed in the Offer Document?	See Section 10.11 (Material contracts) (pages 211 - 221) of the Prospectus which provides a summary of Clarity's material contracts.
Copies of all of the material contracts referred to in the Offer Document	See Folder 4 - Material contracts.
44. If the entity is not an externally managed trust and the following information is included in the Offer Document, the page reference where it is included. Otherwise, either a summary of the material terms of, or a copy of, any employment, service or consultancy agreement the entity or a child entity has entered into with: (a) its CEO or proposed CEO; (b) any of its directors or proposed directors; or (c) any other person or entity who is a related party of the persons referred to in (a) or (b) above (Listing Rule 3.16.4) Note: this requirement does not apply to an externally managed trust. If the entity applying for admission to the official list is an internally managed trust, references to a CEO, proposed CEO, director or proposed director mean a CEO, proposed CEO, director or proposed director of the responsible entity of the trust.	See the following Sections of the Prospectus: - 6.4.2 (Directors' interests and remuneration) (pages 137 - 143); and - 6.7 (Related party transactions) (page 151). See also Folder 5 – Related party agreements.
45. Please enter "Confirmed" in the column to the right to indicate that the material contracts summarised in the Offer Document include, in addition to those mentioned in item 44, any other material contract(s) the entity or a child entity has entered into with:	Confirmed See Section 10.11 (Material contracts) (pages 211 - 221) of the Prospectus.

²³ If the entity applying for admission to the official list is a trust, references to a director mean a director of the responsible entity of the trust.

²⁴ It will assist ASX if the material contracts are provided both in hard copy and in electronic format.

N ^o Item	Location/Confirmation
(a) its CEO or proposed CEO; (b) any of its directors or proposed directors; or (c) any other person or entity who is a related party of the persons referred to in (a) or (b) above Note: this requirement does not apply to an externally managed trust. If the entity applying for admission to the official list is an internally managed trust, references to a CEO, proposed CEO, director or proposed director mean a CEO, proposed CEO, director or proposed director of the responsible entity of the trust.	

46. Please enter "Confirmed" in the column to the right to indicate that all information that a reasonable person would expect to have a material effect on the price or value of the securities to be quoted is included in or provided with this Information Form and Checklist	Confirmed
---	-----------

47. A copy of the entity's most recent annual report	See Folder 6 – Audited accounts and reports (last 2 years) – Docs 6.1 and 6.2
--	---

Entities that are trusts

48. Evidence that the entity is a registered managed investment scheme or has an exemption from ASIC from that requirement (Listing Rule 1.1-Condition 5(a))	N/A
--	-----

49. If the entity is exempted from the requirement to be a registered managed investment scheme, evidence that its responsible entity is either an Australian company or registered as a foreign company carrying on business in Australia under the Corporations Act (Listing Rule 1.1-Condition 5(b))	N/A
---	-----

50. Please enter "Confirmed" in the column to the right to indicate that the responsible entity is not under an obligation to allow a security holder to withdraw from the trust (Listing Rule 1.1-Condition 5(c))	N/A
--	-----

Entities applying under the profit test (Listing Rule 1.2)

51. Evidence that the entity is a going concern or the successor of a going concern (Listing Rule 1.2.1)	N/A
--	-----

52. Evidence that the entity has been in the same main business activity for the last 3 full financial years (Listing Rule 1.2.2)	N/A
---	-----

53. Audited accounts for the last 3 full financial years, including the audit reports (Listing Rule 1.2.3(a))	N/A
---	-----

54. If the entity's last financial year ended more than 6 months and 75 days before the date of this application, audited or reviewed accounts for the last half year (or longer period if available), including the audit report or review (Listing Rule 1.2.3(b))	N/A
---	-----

55. A reviewed pro forma statement of financial position, including the review (Listing Rule 1.2.3(c)) ²⁵	N/A
--	-----

56. Evidence that the entity's aggregated profit from continuing operations for the last 3 full financial years has been at least \$1 million (Listing Rule 1.2.4)	N/A
--	-----

²⁵ The review must be conducted by a registered company auditor (or if the entity is a foreign entity, an overseas equivalent of a registered company auditor) or independent accountant.

Nº Item	Location/Confirmation
57. Evidence that the entity's profit from continuing operations in the past 12 months to a date no more than 2 months before the date of this application has exceeded \$500,000 (Listing Rule 1.2.5)	N/A
58. Is there a statement in the Offer Document that the entity's directors ²⁶ have made enquiries and nothing has come to their attention to suggest that the entity is not continuing to earn profit from continuing operations up to the date of the Offer Document If so, where is it? If not, please attach such a statement signed by all of the entity's directors ²⁷ (Listing Rule 1.2.6)	N/A

Entities applying under the assets test (Listing Rule 1.3)

59. Evidence that the entity has: <ul style="list-style-type: none"> (a) if it is not an investment entity, net tangible assets of at least \$4 million (after deducting the costs of fund raising) or a market capitalisation of at least \$15 million; (b) if it is an investment entity other than pooled development fund, net tangible assets of at least \$15 million; or (c) if it is a pooled development fund, net tangible assets of at least \$2 million (Listing Rule 1.3.1 and 1.3.4) 	See the following Sections of the Prospectus: <ul style="list-style-type: none"> - Key Offer Information (pages 5 - 6) - 1.5 (Key financial information) (page 23); and - 4.7 (Historical and pro forma statement of financial position) (pages 101 - 111).
60. Evidence that: <ul style="list-style-type: none"> (a) at least half of the entity's total tangible assets (after raising any funds) is not cash or in a form readily convertible to cash;²⁸ or (b) there are commitments consistent with its stated objectives under Listing Rule 1.3.3(a) to spend at least half of the entity's cash and assets in a form readily convertible to cash <p>And if (b) above applies, where in the Offer Document is there an expenditure program setting out those commitments (Listing Rule 1.3.2)</p>	See the following Sections of the Prospectus: <ul style="list-style-type: none"> - 1.1 (Overview of Clarity and its business model) (page 10); - 3.6 (Discovery program and research & development) (pages 98 – 99); - 3.7 (Manufacturing and supply strategy) (pages 100 – 102); - 3.8 (Intellectual property) (pages 103 – 104); and - 7.1.3 (Sources and uses of funds) (pages 153 - 154) – the company proposes to use the bulk of the funds allocated to clinical trial to complete the clinical trial programmes as stated in the prospectus.
61. Where in the Offer Document is there a statement setting out the objectives the entity is seeking to achieve from its admission and the offer (Listing Rule 1.3.3(a))?	See the following Sections of the Prospectus: <ul style="list-style-type: none"> - 3 (Company Overview) (pages 74 - 104); - 6.6 (Corporate governance) (page 146); and - 7.1.2 (Purpose of the offer) (page 153).
62. Is there a statement in the Offer Document that the entity has enough working capital at the time of its admission to carry out those stated objectives? If so, where is it?	See the following Sections of the Prospectus: <ul style="list-style-type: none"> - 1.1 (Overview of Clarity and its business model) (page 9);

²⁶ If the entity applying for admission to the official list is a trust, the statement should be made by the directors of the responsible entity of the trust.

²⁷ If the entity applying for admission to the official list is a trust, the statement should be signed by all of the directors of the responsible entity of the trust.

²⁸ In deciding if an entity's total tangible assets are in a form readily convertible to cash, ASX would normally not treat inventories or receivables as readily convertible to cash.

N° Item	Location/Confirmation
If not, attach a statement by an independent expert confirming that the entity has enough working capital to carry out its stated objectives (Listing Rule 1.3.3(b))	<ul style="list-style-type: none"> - 1.4 (Key risks) (page 22); - 4.7.3 (Calculation of the pro forma cash position) (page 111); - 7.1.3 (Sources and uses of funds) (page 154); and - 10.19 (Working capital statement) (page 227).
63. Evidence that the entity's working capital (as shown in its reviewed pro forma statement of financial position under listing Rule 1.3.5(d)) is at least \$1.5 million (Listing Rule 1.3.3(c))	See Section 4.7 (Historical and pro forma statement of financial position) (page 110 - 111) of the Prospectus.
64. Audited accounts for the last 2 full financial years, including the audit reports (Listing Rule 1.3.5(a))	<p>See Section 4 (Financial information) (page 110 - 111) of the Prospectus.</p> <p>See also Folder 6 – Audited accounts and reports (last 2 years).</p>
65. If the entity's last financial year ended more than 6 months and 75 days before the date of this application, audited or reviewed accounts for the last half year (or longer period if available), including the audit report or review (Listing Rule 1.3.5(b))	N/A
66. If the entity has in the 12 months before the date of this application acquired, or is proposing in connection with its application for admission to acquire, another entity or business that is significant in the context of the entity, audited accounts for the last 2 full financial years for that other entity or business, including the audit reports (Listing Rule 1.3.5(c) first bullet point)	N/A
67. If the entity has in the 12 months before the date of this application acquired, or is proposing in connection with its application for admission to acquire, another entity or business that is significant in the context of the entity and the last full financial year for that other entity or business ended more than 6 months and 75 days before the date of this application, audited or reviewed accounts for the last half year (or longer period if available) from the end of the last full financial year for that other entity or business, including the audit report or review (Listing Rule 1.3.5(c) second bullet point)	N/A
68. A reviewed pro forma statement of financial position, including the review (Listing Rule 1.3.5(d)) ²⁹	See Section 4.7 (Historical and pro forma statement of financial position) (page 110 - 111) of the Prospectus.

Entities with restricted securities

69. A statement setting out a list of any person (either on their own or together with associates) who has held a relevant interest in at least 10% of the entity's voting securities at any time in the 12 months before the date of this application	<p>See Doc 8 – ASX Restricted Securities Table (Mandatory Escrow) and Doc 9 – Voluntary Escrow summary (for reference).</p> <p>Relevant parties that held 10% or more in the last 12 months include:</p> <ul style="list-style-type: none"> • TM Ventures Pty Ltd (ACN 128 246 293); and • Cabbit Pty Ltd (ACN 002 108 287).
--	--

²⁹ The review must be conducted by a registered company auditor (or if the entity is a foreign entity, an overseas equivalent of a registered company auditor) or independent accountant.

N° Item	Location/Confirmation
70. A completed ASX Restricted Securities Table ³⁰	See Doc 8 – ASX Restricted Securities Table (Mandatory Escrow) and Doc 9 – Voluntary Escrow summary (for reference).
71. Copies of all restriction deeds (Appendix 9A) entered into in relation to restricted securities (Listing Rule 9.1(b)) ³¹	Restriction deeds to be executed upon ASX confirmation of escrow position.
72. A list of all security holders sent a restriction notice (Appendix 9C) in relation to restricted securities and a sample of the restriction notice (Listing Rule 9.1(c)) ³²	Restriction Notices will be provided upon ASX confirmation of escrow position.
73. If the entity intends to use a third party to maintain its issuer sponsored subregister, a written undertaking from that third party to comply with Listing Rule 9.1(e) (Listing Rule 9.1(f))	To be provided.
74. Are any of the restricted securities in a class that is not intended to be quoted on ASX?	
If so, a sample of the share certificate for the restricted securities with the statement required under Listing Rule 9.1(g)(iii).	N/A
Copies of the undertaking(s) from a bank or recognised trustee to hold the certificates for the restricted securities in escrow (Listing Rule 9.1(g)(iv))	N/A
If the entity intends to use a third party to maintain its certificated subregister, a written undertaking from that third party to comply with Listing Rule 9.1(g) (Listing Rule 9.1(h))	N/A

Entities (other than mining exploration entities and oil and gas exploration entities) with classified assets³³

75. Within the 2 years preceding the date of the entity's application for admission to the official list, has the entity acquired, or entered into an agreement to acquire, a classified asset?	
<p>If so, where in the Offer Document does it disclose:</p> <ul style="list-style-type: none"> • the date of the acquisition or agreement; • full details of the classified asset, including any title particulars; • the name of the vendor; • if the vendor was not the beneficial owner of the classified asset at the date of the acquisition or agreement, the name of the beneficial owner(s); • details of the relationship between the vendor (or, if the vendor was not the beneficial owner of the classified asset at the date of the acquisition 	<p>On the 22 December 2020, the Company entered into 7 patent assignment agreements to be assigned certain patents that were previously licenced to the Company via various licence agreements.</p> <p>The name of the vendor was the University of Melbourne (UOM).</p>

³⁰ An electronic copy of the ASX Restricted Securities Table is available from the ASX Compliance Downloads page on ASX's website.

³¹ ASX will advise which restricted securities are required to be escrowed via a restriction deed under Listing Rule 9.1 as part of the admission and quotation decision. If properly completed restriction deeds and related undertakings have not been provided for all such securities advised by ASX, that will need to be rectified prior to admission occurring and quotation commencing.

³² ASX will advise which restricted securities are required to be escrowed via a restriction notice under Listing Rule 9.1 as part of the admission and quotation decision. If properly completed restriction notices have not been provided to all such securities advised by ASX, that will need to be rectified prior to admission occurring and quotation commencing.

³³ A "classified asset" is defined in Listing Rule 19.12 as:

- (a) an interest in a mining exploration area or oil and gas exploration area or similar tenement or interest;
- (b) an interest in intangible property that is substantially speculative or unproven, or has not been profitably exploited for at least three years, and which entitles the entity to develop, manufacture, market or distribute the property;
- (c) an interest in an asset which, in ASX's opinion, cannot readily be valued; or
- (d) an interest in an entity the substantial proportion of whose assets (held directly, or through a controlled entity) is property of the type referred to in paragraphs (a), (b) and (c) above.

N° Item	Location/Confirmation
<p>or agreement, between the beneficial owner(s) and the entity or any related party or promoter of the entity; and</p> <ul style="list-style-type: none"> • details of the purchase price paid or payable and all other consideration (whether legally enforceable or not) passing directly or indirectly to the vendor. 	<p>UOM and the Company collaborated on the creation and development of various patents, including those detailed above. The initial arrangement between the parties was that the UOM would retain ownership but licence the patents to the Company. With the Company moving into a listed environment, it was agreed between the parties that UOM would assign ownership to the Company.</p> <p>As consideration for the transfer of the patents, the Company has agreed to pay UOM a royalty fee on certain net sales of products associated with the patents at any relevant time in the future as well as on certain licensing arrangements.</p> <p>Details of the assignments are summarised in Section 10.11.14 (Deed of Assignments with The University of Melbourne (UOM)) (page 221) of the Prospectus.</p>
<p>Is the vendor (or, if the vendor was not the beneficial owner of the classified asset at the date of the acquisition or agreement, are any of the beneficial owner(s)) a related party or promoter of the entity?</p> <p>If so, please enter “Confirmed” in the column to the right to indicate that the consideration paid by the entity for the classified asset was solely restricted securities, save to the extent it involved the reimbursement of expenditure incurred by the vendor in developing the classified asset³⁴ or the entity was not required to apply the restrictions in Appendix 9B under Listing Rule 9.2 (Listing Rule 1.1 Condition 11)</p>	<p>N/A</p>
<p>If cash is being paid or proposed to be paid in connection with the acquisition of a classified asset from a related party or promoter, please provide supporting documentation to demonstrate that it was for the reimbursement of expenditure incurred by the vendor in developing the classified asset</p>	<p>N/A</p>
<p>Please also provide a copy of the agreement(s) relating to the acquisition entered into by the entity and any expert’s report or valuation obtained by the entity in relation to the acquisition</p>	<p>N/A</p>
<p>Mining entities</p>	
<p>76. A completed Appendix 1A Information Form and Checklist Annexure 1 (Mining Entities)³⁵</p>	<p>N/A</p>
<p>Oil and gas entities</p>	
<p>77. A completed Appendix 1A Information Form and Checklist Annexure 2 (Oil and Gas Entities)³⁶</p>	<p>N/A</p>

³⁴ ASX may require evidence to support expenditure claims.

³⁵ An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX’s website.

³⁶ An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX’s website.

Nº Item

Location/Confirmation

Entities incorporated or established outside of Australia

~~78. A completed Appendix 1A Information Form and Checklist Annexure 3
(Foreign Entities)³⁷~~

N/A

Externally managed entities

~~79. A completed Appendix 1A Information Form and Checklist Annexure 4
(Externally Managed Entities)³⁸~~

N/A

Stapled entities

~~80. A completed Appendix 1A Information Form and Checklist Annexure 5
(Stapled Entities)³⁹~~

N/A

Further documents to be provided before admission to the official list

In addition to the information and documents mentioned above, entities will be required to provide the following before their admission to the official list and the quotation of their securities commences:

- When available³⁷, 10 printed copies of the final Offer Document (see note 10 above);
- A statement setting out the names of the 20 largest holders in each class of securities to be quoted, and the number and percentage of each class of securities held by those holders;
- A distribution schedule of each class of equity securities to be quoted, setting out the number of holders in the following categories and the total percentage of the securities in that class held by the recipients in each category:
 - 1 - 1,000
 - 1,001 - 5,000
 - 5,001 - 10,000
 - 10,001 - 100,000
 - 100,001 and over
- The number of holders of a parcel of securities (excluding restricted securities or securities subject to voluntary escrow) with a value of more than \$2,000, based on the issue/sale price;
- Any outstanding restriction deeds (Appendix 9A) and related undertakings;⁴⁰
- Any outstanding restriction notices (Appendix 9C);⁴¹ and
- Any other information that ASX may require under Listing Rule 1.17.⁴²

³⁷ An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

³⁸ An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

³⁹ An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

⁴⁰ See note 31 above.

⁴¹ See note 32 above.

⁴² Among other things, this may include evidence to verify that an entity has met Listing Rule 1 Condition 8 and achieved minimum spread without using artificial means (see Guidance Note 1 section 3.9).